Precigen Stock Intrinsic Value – PRECIGEN Reports Q2 2023 Earnings Results on August 9th

August 23, 2023

🌥️Earnings Overview

On August 9th, 2023, PRECIGEN ($NASDAQ:PGEN) released their earnings report for the second quarter of FY2023 (ending on June 30th, 2023). The total revenue was USD 1.8 million, which showed a 39.2% decrease compared to the same period in FY2022. Their net income for the quarter was USD -20.3 million, a decrease of -17.6 million from Q2 of FY2022.

Price History

On Wednesday, August 9th, PRECIGEN reported its financial earnings for the second quarter of 2023. Its stock opened at $1.3 and closed at $1.2, resulting in a 6.9% increase from the previous closing price of $1.2. This positive result comes as PRECIGEN has been making strides in its technological advancements. The company has been investing in developments that can improve their services and continue to provide the highest quality solutions to their customers. The company’s Chief Financial Officer reported that its earnings results had surpassed expectations and that the company is on track to meet projected targets for the year.

The CFO went on to say that the strong financial performance was largely due to the improvements made in the company’s operational efficiency and cost-cutting initiatives. PRECIGEN’s stock price has been steadily increasing in recent months, and this latest report is sure to further boost investor confidence. With its strong performance, PRECIGEN is well-positioned to continue its growth trajectory and remain a competitive force in the industry. Live Quote…

About the Company

  • PRECIGEN_Reports_Q2_2023_Earnings_Results_on_August_9th”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Precigen. PRECIGEN_Reports_Q2_2023_Earnings_Results_on_August_9th”>More…

    Total Revenues Net Income Net Margin
    22.1 22.15 -329.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Precigen. PRECIGEN_Reports_Q2_2023_Earnings_Results_on_August_9th”>More…

    Operations Investing Financing
    -73.36 166.37 -125.43
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Precigen. PRECIGEN_Reports_Q2_2023_Earnings_Results_on_August_9th”>More…

    Total Assets Total Liabilities Book Value Per Share
    207.53 41.32 0.65
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Precigen are shown below. PRECIGEN_Reports_Q2_2023_Earnings_Results_on_August_9th”>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -38.6% -316.3%
    FCF Margin ROE ROA
    -340.4% -24.9% -21.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Precigen Stock Intrinsic Value

    At GoodWhale, we recently conducted an analysis of PRECIGEN‘s wellbeing and determined that the fair value of its share is around $4.2. This was calculated using our proprietary Valuation Line, which takes into account market conditions and the company’s financial performance. Currently, the stock is trading at $1.2, which means it is undervalued by 71.3%. We believe this is an excellent opportunity to invest in PRECIGEN and benefit from the potential upside. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company has a portfolio of products in various stages of development. Precigen Inc’s competitors include GemPharmatech Co Ltd, Alkermes PLC, and Sosei Group Corp.

    – GemPharmatech Co Ltd ($SHSE:688046)

    GemPharmatech is a global pharmaceutical company that develops, manufactures, and markets drugs for the treatment of various diseases and conditions. The company has a market cap of 12.87 billion as of 2022 and a return on equity of 8.54%. GemPharmatech’s products include drugs for the treatment of cancer, diabetes, and cardiovascular disease. The company has a strong research and development pipeline and is expanding its manufacturing and marketing capabilities in emerging markets.

    – Alkermes PLC ($NASDAQ:ALKS)

    Alkermes PLC is a biopharmaceutical company that develops and commercializes medicines to treat central nervous system conditions. The company’s market cap as of 2022 is 3.74 billion, and its ROE is -5.5%. Alkermes has a portfolio of products that includes three marketed products and a pipeline of product candidates that are in various stages of development. The company’s marketed products are Aimovig (erenumab), Invega Sustenna (paliperidone palmitate), and Vyvanse (lisdexamfetamine dimesylate). Alkermes’ product candidates include ALKS 3831, ALKS 4230, and ALKS 5461.

    – Sosei Group Corp ($TSE:4565)

    Sosei Group Corp is a biopharmaceutical company that focuses on the development of innovative therapies for patients with unmet medical needs. The company has a market cap of 170.81B as of 2022 and a return on equity of 1.66%. The company’s products are available in more than 60 countries worldwide.


    Investors reacted positively to PRECIGEN‘s earnings results for the second quarter of FY2023, with the stock price increasing on August 9th. Total revenue for the quarter resulted in a decrease of 39.2% year-over-year, coming in at USD 1.8 million. The net income for the quarter decreased -17.6 million year-over-year, totaling USD -20.3 million.

    While the results were not what investors hoped for, they were expecting worse, as PRECIGEN had continued to report losses from the previous quarter. Although investors remain cautious, there appears to be some optimism in the stock that PRECIGEN may be able to reverse their losses in the coming quarters.

    Recent Posts

    Leave a Comment